Adam L Boxer

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia
    Adam L Boxer
    Memory and Aging Center and the Department of Neurology, University of California at San Francisco, 94143, USA
    Arch Neurol 60:949-56. 2003
  2. pmc Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California at San Francisco, 94143 1207, USA
    Neurology 61:1485-91. 2003
  3. ncbi request reprint Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment
    A L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, CA 94143 1207, USA
    Neurology 64:1431-4. 2005
  4. ncbi request reprint Clinical features of frontotemporal dementia
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, California 94143 1207, USA
    Alzheimer Dis Assoc Disord 19:S3-6. 2005
  5. pmc Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features
    Sharon J Sha
    Department of Neurology, University of California, San Francisco, USA
    Neurology 79:1002-11. 2012
  6. pmc Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, CA 94143 1207, USA
    Arch Neurol 69:509-17. 2012
  7. pmc Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease
    Katherine P Rankin
    University of California San Francisco, San Francisco, CA, USA
    J Mol Neurosci 45:594-608. 2011
  8. pmc Anti-saccade performance predicts executive function and brain structure in normal elders
    Jacob B Mirsky
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA 94143, USA
    Cogn Behav Neurol 24:50-8. 2011
  9. pmc Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
  10. pmc Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
    Siobhan Garbutt
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Brain 131:1268-81. 2008

Research Grants

Detail Information

Publications31

  1. ncbi request reprint Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia
    Adam L Boxer
    Memory and Aging Center and the Department of Neurology, University of California at San Francisco, 94143, USA
    Arch Neurol 60:949-56. 2003
    ..Progressive brain atrophy is associated with Alzheimer disease (AD) and other dementias. Regional differences in brain atrophy may reflect clinical features of disease...
  2. pmc Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California at San Francisco, 94143 1207, USA
    Neurology 61:1485-91. 2003
    ..To explore the structural neuroimaging correlates of visual constructive impairment in patients with mild to moderate Alzheimer disease (AD)...
  3. ncbi request reprint Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment
    A L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, CA 94143 1207, USA
    Neurology 64:1431-4. 2005
    ..These findings suggest that homocysteine-related cognitive impairment may be partially reversible...
  4. ncbi request reprint Clinical features of frontotemporal dementia
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, California 94143 1207, USA
    Alzheimer Dis Assoc Disord 19:S3-6. 2005
    ....
  5. pmc Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features
    Sharon J Sha
    Department of Neurology, University of California, San Francisco, USA
    Neurology 79:1002-11. 2012
    ..To describe the phenotype of patients with C9FTD/ALS (C9ORF72) hexanucleotide repeat expansion...
  6. pmc Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, CA 94143 1207, USA
    Arch Neurol 69:509-17. 2012
    ..Deficits in the generation and control of saccades have been described in clinically defined frontotemporal dementia (FTD) and Alzheimer disease (AD)...
  7. pmc Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease
    Katherine P Rankin
    University of California San Francisco, San Francisco, CA, USA
    J Mol Neurosci 45:594-608. 2011
    ..Despite a remarkable overlap between the two patient types, bvFTD patients with underlying CBD pathology show subtle clinical features that may distinguish them from patients with Pick's disease neuropathology...
  8. pmc Anti-saccade performance predicts executive function and brain structure in normal elders
    Jacob B Mirsky
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA 94143, USA
    Cogn Behav Neurol 24:50-8. 2011
    ..To assess the neuropsychological and anatomical correlates of anti-saccade (AS) task performance in normal elders...
  9. pmc Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
    ..The atrophy patterns in epsilon4 carriers may indicate that they are at greater risk for clinical progression...
  10. pmc Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
    Siobhan Garbutt
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Brain 131:1268-81. 2008
    ..These data suggest that oculomotor assessment may aid in the diagnosis of FTLD and related disorders...
  11. pmc Visual search patterns in semantic dementia show paradoxical facilitation of binding processes
    Indre V Viskontas
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, 350 Parnassus Ave, Ste 905, San Francisco, CA 94143, USA
    Neuropsychologia 49:468-78. 2011
    ....
  12. pmc Gray matter correlates of set-shifting among neurodegenerative disease, mild cognitive impairment, and healthy older adults
    Judy Pa
    Alzheimer Disease Research Center, Dept of Neurology, University of California, San Francisco, California, USA
    J Int Neuropsychol Soc 16:640-50. 2010
    ..Overall, these findings highlight the neuroanatomical correlates of set-shifting and the importance of controlling for component processes when investigating complex cognitive tasks...
  13. ncbi request reprint Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Arch Neurol 63:81-6. 2006
    ..Progressive brain atrophy is associated with the corticobasal degeneration syndrome (CBDS) and progressive supranuclear palsy (PSP). Regional differences in brain atrophy may reflect the clinical features of disease...
  14. pmc Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias
    Katherine L Possin
    From the Department of Neurology K L P, D F, K P R, A L B, K W, B L M, J H K, Memory and Aging Center, University of California, San Francisco and Mayo Clinic G E S, S M H, Rochester, MN
    Neurology 80:2180-5. 2013
    ..The objective of this study was to determine which aspects of executive functions are most affected in behavioral variant frontotemporal dementia (bvFTD) and best differentiate this syndrome from Alzheimer disease (AD)...
  15. pmc Patterns of striatal degeneration in frontotemporal dementia
    Cathra Halabi
    Departments of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Alzheimer Dis Assoc Disord 27:74-83. 2013
    ..These results demonstrate that ventral striatum degeneration is a prominent shared feature in behavioral variant frontotemporal dementia and semantic dementia and may contribute to the social-emotional deficits common to both disorders...
  16. pmc Off-label medication use in frontotemporal dementia
    - Bei Hu
    Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
    Am J Alzheimers Dis Other Demen 25:128-33. 2010
    ..We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics...
  17. pmc Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration
    Adam L Boxer
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    J Neurosci 26:6354-63. 2006
    ....
  18. pmc Baseline predictors of clinical progression among patients with dysexecutive mild cognitive impairment
    Julene K Johnson
    Institute for Health and Aging, University of California, San Francisco, USA
    Dement Geriatr Cogn Disord 30:344-51. 2010
    ..The purpose of this study was to evaluate baseline predictors of clinical progression after 2 years for patients with dysexecutive MCI (dMCI), a single-domain non-amnestic MCI subgroup...
  19. pmc Intrinsic connectivity network disruption in progressive supranuclear palsy
    Raquel C Gardner
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
    Ann Neurol 73:603-16. 2013
    ..Progressive supranuclear palsy (PSP) has been conceptualized as a large-scale network disruption, but the specific network targeted has not been fully characterized. We sought to delineate the affected network in patients with clinical PSP...
  20. ncbi request reprint Clinical and neuropsychological features of corticobasal degeneration
    Nataliya Belfor
    University of California San Francisco, Memory and Aging Center, 350 Parnassus Avenue, Suite 705, 94143, USA
    Mech Ageing Dev 127:203-7. 2006
    ..Increasing awareness of this disorder has led to the realization that specific cognitive and imaging changes are common with CBD degeneration and that these changes help with clinical diagnosis...
  21. pmc Clinicopathological correlations in corticobasal degeneration
    Suzee E Lee
    Memory and Aging Center, University of California San Francisco, San Francisco, CA 94143, USA
    Ann Neurol 70:327-40. 2011
    ..To characterize cognitive and behavioral features, physical findings, and brain atrophy patterns in pathology-proven corticobasal degeneration (CBD) and corticobasal syndrome (CBS) with known histopathology...
  22. pmc Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family
    Adam L Boxer
    UCSF Memory and Aging Center, University of California San Francisco, CA 94143, USA
    J Neurol Neurosurg Psychiatry 82:196-203. 2011
    ..Previous studies have identified a region on chromosome 9p that is associated with FTD and ALS...
  23. pmc Deformation-based morphometry reveals brain atrophy in frontotemporal dementia
    Valerie A Cardenas
    Magnetic Resonance Unit, San Francisco Veterans Affairs Medical Center, CA 94121, USA
    Arch Neurol 64:873-7. 2007
    ..To compare deformation-based maps of local anatomical size between subjects with frontotemporal dementia (FTD) and healthy subjects to identify regions of the brain involved in FTD...
  24. ncbi request reprint Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Neurology 69:283-90. 2007
    ..To compare the in vivo uptake of two amyloid-binding PET agents, PIB and FDDNP, in human subjects with a prion protein (PrP) gene (PRNP) mutation that produces a clinical syndrome similar to Alzheimer disease (AD)...
  25. pmc Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Lancet Neurol 12:149-56. 2013
    ..A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD...
  26. pmc An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA 94143 1207, USA
    Alzheimer Dis Assoc Disord 23:211-7. 2009
    ..Memantine was well-tolerated in these subjects. Future placebo-controlled trials of memantine in FTLD are warranted and may have greater power to detect behavioral and cognitive effects if focused on the FTD and SD clinical syndromes...
  27. pmc The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Alzheimers Dement 9:189-98. 2013
    ..We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies...
  28. pmc Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
    Baber K Khan
    Department of Neurology, University of California San Francisco, San Francisco, CA, USA
    J Neurol Neurosurg Psychiatry 83:358-64. 2012
    ..Here, two patients with bvFTD-SP with chromosome 9 open reading frame 72 (C9ORF72) hexanucleotide expansions are described...
  29. ncbi request reprint Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Alzheimer Dis Assoc Disord 21:S79-87. 2007
    ..In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed...
  30. doi request reprint TDP-43 frontotemporal lobar degeneration and autoimmune disease
    Zachary A Miller
    UCSF Memory and Aging Center, University of California San Francisco, San Francisco, California 94143 1207, USA
    J Neurol Neurosurg Psychiatry 84:956-62. 2013
    ..Given the association between systemic inflammation and other neurodegenerative processes, links between autoimmunity and FTD need to be explored...
  31. pmc Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases
    Giovanni Coppola
    Department of Neurology, University of California, Los Angeles, CA, USA
    Hum Mol Genet 21:3500-12. 2012
    ....

Research Grants1

  1. Ocular motor function and decision-making in FTLD
    Adam Boxer; Fiscal Year: 2007
    ....